Implementing IMD Serogroup B Vaccination for Pediatric Patients
Invasive meningococcal disease (IMD) is an acute and serious disease that can result in death. Key differences exist between the IMD vaccines that are available in Canada, such as the meningococcal serogroups that they protect against and the age indications for use.
Using a pediatric patient case, this program will review the prevalence of different meningococcal serogroups in Canada, along with the differences between currently available vaccines. The overall goal of the program is to increase clinicians’ confidence in discussing IMD vaccination with their patients and recommending appropriate vaccination.
This CME has been supported by educational funding from GSK Grant.
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.25 Mainpro+ Credits.
This program is developed in collaboration with Partners in Progressive Medical Education (PPME).
James Kim, MBBCh, PgDip
Vivien Brown, MDCM, CCFP, FCFP, NCMP
Marla Shapiro, C.M.
Angel Chu, CCFP, MHSc, FRCPC, FCFP, NCMP
Upon completion of this continuing education program participants will be better able to:
- Discuss the clinical significance of invasive meningococcal disease (IMD).
- Describe the prevalence of different meningococcal serogroups in Canada.
- Differentiate between the currently available vaccines for IMD.
- Summarize the real word evidence gathered from the use of 4CMenB.